Fig. 1: Cyclin E1 is elevated in BRCA1 deficient cancers, and predicts poor prognosis.
From: Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
a Microscope images of high and low expression of cyclin E1 (IHC). Scale bar is 50 µm. b Cyclin E1 protein expression (H score) in wildtype, BRCA1, BRCA2, and PALB2/CHEK2 mutated cancers, analysis by one-way ANOVA; *p < 0.05; ****p < 0.0001. Box and whisker plots show error bars of minimum to maximum, where the box extends from the 25th to the 75th percentile, and the line in the middle of the box indicates the median. c Scatter plot of TCGA breast cancer cohort cyclin E1 protein expression (RPPA) versus BRCA1 methylation by HM27 array. Dashed line indicates cut-off between methylated and non-methylated. Correlation analysis of cyclin E1 protein and BRCA1 methylation performed across the methylated subset, r = Spearman coefficient. d Kaplan–Meier curves of overall survival in the KConfab cohort comparing BRCA1 mutated cyclin E1 high cases versus BRCA1 mutated cyclin E1 low cases. e Microscope images of 19q12 non-amplified and 19q12 amplified breast cancer cases (ISH); inset shows representative example of each. Scale bar is 20 µm. f Scatter plot of cyclin E1 protein expression versus CCNE1 (19q12/INSR ratio) amplification status in the KConfab cohort. r = Spearman coefficient. g 19q12/INSR ratio (ISH) cases compared to each of wild type, BRCA1, BRCA2, PALB2/CHK2 mutated cancers in the KConfab Cohort, analyzed by one-way ANOVA; **p < 0.01. Box and whisker plots show error bars of minimum to maximum, where the box extends from the 25th to the 75th percentile, and the line in the middle of the box indicates the median. h Kaplan–Meier curves of overall survival of BRCA1 mutated breast cancer comparing 19q12 amplified and non-amplified subsets.
